Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Jakavi | Ruxolitinib | Polycythemia vera | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | Ruxolitinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Izba | travoprost ophthalmic solution | Glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
| Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | ||
| Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
| Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete |
Last Updated : May 19, 2024